Available from Deakin Research Online: Copyright : 2009 The Authors
|
|
- Ashley Cunningham
- 5 years ago
- Views:
Transcription
1 Deakin Research Online Deakin University s institutional research repository DDeakin Research Online Research Online This is the authors final peer reviewed version of the item published as: Cameron, A. J., Zimmet, P. Z., Shaw, J. E. and Alberti, K. G. M. M , The metabolic syndrome : in need of a global mission statement, Diabetic medicine, vol. 26, no. 3, pp Available from Deakin Research Online: Copyright : 2009 The Authors The definitive version is available at
2 The Metabolic Syndrome: in need of a global mission statement. Word count: 2037 words Adrian J Cameron epidemiologist, Department of Epidemiology and Clinical Diabetes, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia Paul Z Zimmet director emeritus and director of international research, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia Jonathan E Shaw associate director, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia KGMM Alberti professor, Department of Medicine, University of Newcastle upon Tyne Funding: AC is supported by Postgraduate Research Scholarship PP04M1794 from the National Heart Foundation of Australia. Aims The value of clinical definitions of the metabolic syndrome has been questioned, with confusion surrounding their intended use and purpose. Our aim was to construct a mission statement that outlines the value of the metabolic syndrome in clinical and public health settings. Methods Case studies have been used to demonstrate three key points. Results We argue here for recognition of obesity as being a crucial element within the metabolic syndrome but perhaps even more important before its development. We also contend that the concept does indeed have a role as a risk prediction tool, and that it could provide a useful metric for the scale and progress of the looming global epidemic of diabetes and cardiovascular disease.
3 Conclusions Through appreciation of its purpose, and recognition of both its limitations and those attributes that make it unique and valuable, we believe we have demonstrated here that the metabolic syndrome deserves its place in the global toolbox of diabetes and CVD prevention. The metabolic syndrome has suffered from a lack of clarity regarding its intended use and raison d etre. This has led some to question its value in clinical practice and as a public health tool.[1, 2] The major stated rationale for the main definitions of the syndrome is to identify patients at high risk of clinical atherosclerotic disease and type 2 diabetes mellitus in order to institute preventive measures to reduce these risks.[3, 4] In addition, the International Diabetes Federation (IDF) definition of the metabolic syndrome, in particular, was designed to be useful globally in primary as well as specialist care, and in resource poor settings. Recent reports indicate that even though the metabolic syndrome does independently predict both cardiovascular disease and type 2 diabetes, it is not necessarily the most effective tool for this purpose.[5-8] Doubt about the utility of the syndrome in clinical practice means that it is timely to consider whether the current high level of interest in the metabolic syndrome is misplaced, or if it does indeed deserve an important place in the global fight against diabetes and cardiovascular disease (CVD). We propose here that the attributes of the metabolic syndrome that make it a potentially valuable global public health tool are the emphasis it places on central obesity (although we contend that this emphasis requires a subtle shift), its ability to identify high risk individuals at a young age and the possibilities provided by its dichotomous structure.
4 Obesity: important in the metabolic syndrome, more important before the syndrome develops We will begin our explanation of this view by focusing on obesity and its role in the syndrome. A thirty year old male has a waist circumference of 130cm (and a BMI of 35kg/m 2 ) and is therefore markedly obese, but doesn t (yet) have the hypertension, dyslipidaemia or elevated blood glucose characteristic of the metabolic syndrome. Q. What is his risk of diabetes using available calculators? A. Low (using the Finnish diabetes risk score,[9] even if he also does no exercise and never eats fruit or vegetables (but is without a family history of diabetes), his 10 year diabetes risk is described as only slightly elevated. Using the San Antonio Heart study diabetes prediction model,[10] with a fasting plasma glucose of 5.0 mmol/l and normal blood pressure and HDL cholesterol readings, he has a 7.5 year risk of developing diabetes of <5%) Q. What is his risk of coronary heart disease using available calculators? A. Negligible. (Even with a substantial risk factor burden, 10 year CHD risk estimates in young men have been shown to remain low.[11] In this case, it is only 1%.[12]) Q. Those calculators all estimate only short term risk (10 years or less). Is he at high lifetime risk of these conditions? A. Absolutely (Obesity is a major risk factor for diabetes, and its strong relationship with CHD morbidity and mortality becomes apparent with longer-term followup.[13-15]
5 Q. Does his low short term risk and the fact that he does not meet the criteria for the metabolic syndrome mean that he does not need to try to reduce his risk? A. Absolutely not. His extreme obesity at such a young age means a very high lifetime risk of developing the other components of the MetS, and subsequent CHD and diabetes. Indeed, his young age means a longer time at risk and the potential for greater expense, disability and suffering. His childhood and early adulthood were actually the best time to intervene when behaviour is more modifiable. But better late than never. This example serves to highlight the importance of recognizing that obesity is a risk factor in its own right, and one that can often be present before the appearance of the metabolic syndrome proper. The emphasis on obesity in a definition of the metabolic syndrome is perhaps less important than acknowledging that obesity is the most important modifiable risk factor before the metabolic syndrome even develops. Our recent research supports this view, demonstrating that central obesity precedes deterioration in each of the components that constitute the metabolic syndrome.[16] As a metaphor, obesity can be thought of as the sea retreating before the tsunami of metabolic syndrome, then diabetes and CVD roll in. The important role of obesity in the metabolic syndrome is as a warning sign for future disease, not as a correlate for disease that is already present. The Japanese government has clearly understood this, recently announcing laws requiring all companies and local governments to measure waistlines of their year old employees annually (44% of the entire Japanese population).[17] We suggest that definitions of the metabolic syndrome need to acknowledge this important point, recognising the importance of
6 obesity in the metabolic syndrome, but placing greater emphasis on the role of obesity before the metabolic syndrome has even developed. Having said this, it is also important to recognize that a sub-population of obese patients may exist who will remain metabolically healthy despite their excess body fat, and who may be protected against obesity-related metabolic complications.[18] The metabolic syndrome: a CVD and type 2 diabetes risk prediction tool after all Q. If this young man from our earlier example also had hypertension (systolic BP 150mmHg) and total cholesterol of 6.5mmol/L and met the criteria for the metabolic syndrome, which of the metabolic syndrome or a CVD risk algorithm would identify him as someone at high future CVD risk? A. His 10 year calculated risk of CHD[12] is still only 1%, and even if he was also a smoker, this would still be less than 10%. By meeting the criteria for the metabolic syndrome, however, this individual is clearly identified as someone at high lifetime risk of CVD and diabetes. Indeed, Sundstrom et al. recently demonstrated the long term value of the metabolic syndrome in predicting total and cardiovascular mortality independently of age, smoking, diabetes, hypertension and cholesterol.[19] Because of the influence of age in risk prediction models and the fact that they only predict short term risk, the importance of risk factors such as obesity in younger people is often ignored. The opportunity for preventive intervention is ripe well before most people will qualify as high risk on risk prediction models, which are often difficult to use and interpret.[20] It is the high lifetime risk which is more important than the comparatively low 10 year risk. The absence of an age criterion in definitions of the metabolic
7 syndrome, while reducing its overall predictive ability, means that it goes some way to recognizing that those with signs of serious metabolic deterioration at a young age are at very high lifetime risk of diabetes and CVD. It has now become clear that the metabolic syndrome is not the best predictor of global cardiovascular or diabetes risk and misses those persons whose risk is not mediated by metabolic syndrome parameters.[21, 22] For these reasons, and because clinical definitions do not acknowledge increasing numbers or severity of components as an even greater risk, the arguments we have made for the value of the syndrome need to be kept in context. In isolation, the metabolic syndrome is an imperfect tool for the identification of those at high risk of future CHD or diabetes. In combination with the knowledge that other risk factors for these conditions are also important, and used in combination with good clinical judgment and other appropriate tools, the metabolic syndrome does, however, have an important clinical function. It highlights the role obesity often plays in metabolic deterioration. It can help patients understand the inter-related nature of the syndrome s components and finally, when present it suggests the need for intensive intervention to prevent diabetes and CVD. Just as measurement of obesity in itself is not the optimal tool for CHD or diabetes risk prediction, neither is the metabolic syndrome (or any other risk prediction device). Each, however, has characteristics that make them important clinical and public health tools. The metabolic syndrome: more than just risk prediction We conclude by suggesting that the debate surrounding the metabolic syndrome s risk prediction qualities has meant that other important features of the syndrome have been ignored. We demonstrate the public health value of the metabolic syndrome by answering some of the key questions relating to its mission statement, and by suggesting an alternative perspective on the utility of the concept.
8 Q. Was the metabolic syndrome designed to be the optimal short to medium term risk prediction device for CVD or diabetes? A. No, as we discussed earlier, it is obvious that other risk factors specific to these two conditions (as well as age and sex) would be required to determine risk optimally. It is important to acknowledge, however, that all available risk prediction devices have flaws and none can be used as the sole basis for clinical decisions. The metabolic syndrome as currently defined was never intended as an absolute risk indicator rather as an early warning system. Q. Does a diagnosis of the metabolic syndrome actually identify a population at high risk of CVD and diabetes? A. Yes, as has been repeatedly shown.[23] Q. Other than predicting absolute CVD and type 2 diabetes risk (for which it, as well as all other available risk prediction devices, are imperfect), are there other features of the metabolic syndrome that provide further value? A. We contend that in addition to the important clinical attributes identified earlier, an under-recognised use for the metabolic syndrome is a global metric that identifies a looming epidemic of CVD and diabetes. Q. How will the coming global diabetes epidemic (most of which will occur in developing countries)[24] and the resultant CVD be prevented? A. Identification of those at high short term risk of diabetes and CVD and intensive medical intervention can only be a small part of the solution, particularly in developing countries. Population level lifestyle modification requires a big picture approach that addresses the structural and environmental causes of an obesogenic environment and is reliant on support of all levels of government, the public as well as health care providers.
9 We explain below how the metabolic syndrome helps each of these stakeholders do just this. Two pieces of information that will help any country appreciate the urgency of implementing measures to prevent diabetes and CVD, and chart their progress toward that aim, are the prevalence of obesity (the warning of a tsunami to come), and the prevalence of the metabolic syndrome (how much of the tsunami has already arrived). As a metric, the metabolic syndrome allows comparisons of the scale of the tsunami both between countries (at least those of similar ethnicity) and across time, with all of its elements being modifiable through lifestyle alteration. Although often under-appreciated, quantifying the magnitude of a problem and how it changes over time is crucial for public and political awareness, and to inform funding decisions and preventive measures. Over the previous few decades, tracking the trends in smoking, hypertension and cholesterol might have been a good way of predicting future changes in CVD. As the importance of CVD risk factors shifts to metabolic abnormalities and obesity, the metabolic syndrome may have a valuable role to play in predicting future disease burden, and one that cannot be filled by other risk prediction models. In conclusion, the metabolic syndrome was not designed to be a tool that optimally predicts absolute risk of future CVD and type 2 diabetes. It is clear, however, that those with the metabolic syndrome do constitute a population at high risk of both. We have demonstrated here that a diagnosis of the metabolic syndrome can add valuable information regarding future risk, particularly among the young, and should therefore be seen as an additional device in the toolbox of diabetes and CVD prevention. As a metric allowing comparison of the scale of an impending epidemic between countries or
10 population groups and across time, the metabolic syndrome differentiates itself as a unique tool for the global prevention of diabetes and CVD. The emphasis on central obesity in the metabolic syndrome should be as a pre-cursor to the development of the syndrome itself, not as a correlate for disease that is already present, with lifestyle intervention being important as soon as obesity is present, particularly in the young. To build on the considerable awareness of the metabolic syndrome and achieve the potential we have identified, a single global definition (with appropriate consideration of ethnic differences) is imperative. By ensuring that obesity is recognised as an important warning sign before the metabolic syndrome even appears, and recognising and appreciating those attributes that make the concept unique and valuable, the metabolic syndrome should be a much needed tool in the campaign to prevent the devastating consequences of a global diabetes and CVD epidemic. Declaration of Competing Interests: Nothing to declare. References 1 Greenland, P. Critical questions about the metabolic syndrome. Circulation 2005; 112: Kahn, R, Buse J, Ferrannini E, Stern M. The Metabolic Syndrome: Time for a Critical Appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: Alberti, KG, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. Lancet 2005; 366: Grundy, SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: e285-e Sattar, N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet, 2008; 371: Wannamethee, SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005; 165:
11 7 Cameron, AJ, Magliano DJ, Zimmet PZ, Welborn TA, Colagiuri S, Tonkin AM et al. The metabolic syndrome as a tool for predicting future diabetes: the AusDiab study. J Intern Med 2008; 264: Stern, MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004; 27: Lindstrom, J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003; 26: Stern, MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Inter Med 2002; 136: Berry, JD, Lloyd-Jones DM, Garside DB, Greenland P. Framingham risk score and prediction of coronary heart disease death in young men. Am Heart J 2007; 154: National Cholesterol Education Program (Adult Treatment Panel III). Risk Assessment Tool for Estimating 10-year Risk of Developing Hard CHD (Myocardial Infarction and Coronary Death). Available at: last accessed 26 June Lloyd-Jones, DM, Wilson PW, Larson MG, Beiser A, Leip EP, D'Agostino RB et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol 2004; 94: Spataro, JA, Dyer AR, Stamler J, Shekelle RB, Greenlund K, Garside D. Measures of adiposity and coronary heart disease mortality in the Chicago Western Electric Company Study. J Clin Epidemiol, 1996; 49: Yan, LL, Daviglus ML, Liu K, Stamler J, Wang R, Pirzada A et al. Midlife body mass index and hospitalization and mortality in older age. J Am Med Assoc 2006; 295: Cameron, AJ, Boyko EJ, Sicree RA, Zimmet PZ, Soderberg S, Alberti KGMM et al. Central obesity as a precursor to the metabolic syndrome in the AusDiab study and Mauritius. Obesity 2008; 16: Onishi, N. Japan, Seeking Trim Waists, Measures Millions. New York Times Available at: last accessed 18 June Karelis, AD. Metabolically healthy but obese individuals. Lancet 2008; 372: Sundstrom, J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. Br Med J 2006; 332: McManus, RJ, Mant J, Meulendijks CF, Salter RA, Pattison HM, Roalfe AK et al. Comparison of estimates and calculations of risk of coronary heart disease by doctors and nurses using different calculation tools in general practice: cross sectional study. Br Med J 2002; 324:
12 21 Despres, JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: Sattar, N. Why metabolic syndrome criteria have not made prime time: a view from the clinic. Int J Obes 2008; 32(Suppl 2): S30-S Ford, ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: International Diabetes Federation. Diabetes Atlas, 3rd edn. Brussels: International Diabetes Federation, 2006.
Available from Deakin Research Online: Copyright : 2009, Elsevier Ireland Ltd
Deakin Research Online Deakin University s institutional research repository DDeakin Research Online Research Online This is the authors final peer reviewed version of the item published as: Cameron, Adrian
More informationMetabolic Syndrome: What s in a name?
Commentary Metabolic Syndrome: What s in a name? Deborah P. Wubben, MD, MPH; Alexandra K. Adams, MD, PhD Abstract The term metabolic syndrome has recently become en vogue. But is the definition realistic,
More informationCVD.
149-158(2 )8 1387. - : () - :. : (HR)... () :... [HR: /(CI: / )] [HR:/(/-/) ]... :. - : - : : - : - : - fzhadaegh@endocrine.ac.ir 87/9/11: 87/8/29 : 87/7/3 : ... - : 15 TLGS.. ) -. ( (OGTT) ( ).. ( / )...
More informationAvailable from Deakin Research Online: Copyright : 2007, International Diabetes Institute
Deakin Research Online Deakin University s institutional research repository DDeakin Research Online Research Online This is the authors final peer reviewed version of the item published as: Cameron, A.
More informationCardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study
(28) 32, S11 S16 & 28 Nature Publishing Group All rights reserved 37-6/8 $3. www.nature.com/ijo ORIGINAL ARTICLE Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationMetabolic Syndrome among Type-2 Diabetic Patients in Benghazi- Libya: A pilot study. Arab Medical University. Benghazi, Libya
Original Article Metabolic Syndrome among Type-2 Diabetic Patients in Benghazi- Libya: A pilot study Alshkri MM 1, Elmehdawi RR 2 1 Benghazi Diabetes Center. 2 Medical Department, Faculty of Medicine,
More informationRisk Factors for Heart Disease
Developmental Perspectives on Health Disparities from Conception Through Adulthood Risk Factors for Heart Disease Philip Greenland, MD Harry W. Dingman Professor Chair, Department of Preventive Medicine
More informationMetabolic Syndrome: Why Should We Look For It?
021-CardioCase 29/05/06 15:04 Page 21 Metabolic Syndrome: Why Should We Look For It? Dafna Rippel, MD, MHA and Andrew Ignaszewski, MD, FRCPC CardioCase presentation Andy s fatigue Andy, 47, comes to you
More informationGlobal Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic. Syndrome. and Nathan D. Wong, PhD, MPH
Diabetes Care Publish Ahead of Print, published online April 1, 2008 Global Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic Syndrome Khiet C. Hoang MD, Heli Ghandehari, BS, Victor
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.043
More informationYOUNG ADULT MEN AND MIDDLEaged
BRIEF REPORT Favorable Cardiovascular Profile in Young Women and Long-term of Cardiovascular and All-Cause Mortality Martha L. Daviglus, MD, PhD Jeremiah Stamler, MD Amber Pirzada, MD Lijing L. Yan, PhD,
More informationDiabetes, Diet and SMI: How can we make a difference?
Diabetes, Diet and SMI: How can we make a difference? Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Relative
More informationAge and Sex Differences the Clustering of Metabolic Syndrome Factors: Association with Mortality Risk
Diabetes Care Publish Ahead of Print, published online August 10, 2010 Metabolic Syndrome Combinations and Mortality Age and Sex Differences the Clustering of Metabolic Syndrome Factors: Association with
More informationImpact of Metabolic Syndrome Compared With Impaired Fasting Glucose on the Development of Type 2 Diabetes in a General Japanese Population
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Impact of Metabolic Syndrome Compared With Impaired Fasting Glucose on the Development of Type 2 Diabetes in a General Japanese Population
More information8/15/2018. Promoting Education, Referral and Treatment for Patients Presenting with Metabolic Syndrome. Metabolic Syndrome.
Promoting Education, Referral and Treatment for Patients Presenting with Metabolic Syndrome Diagnostic Criteria (3/5) Metabolic Syndrome Key Facts JAN BRIONES DNP, APRN, CNP FAMILY NURSE PRACTITIONER Abdominal
More informationAssociation between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese
Diabetes Care Publish Ahead of Print, published online June 12, 2008 Raised Blood Pressure and Dysglycemia Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese Bernard My Cheung,
More informationD. Hilton. Keywords Epidemiological methods, aging, prevalence.
Computational Methods in Official Statistics with an Example on Calculating and Predicting Diabetes Mellitus [DM] Prevalence in Different Age Groups within Australia in Future Years, in Light of the Aging
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationDiabetes Care 31: , 2008
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Global Coronary Heart Disease Risk Assessment of Individuals With the Metabolic Syndrome in the U.S. KHIET C. HOANG, MD HELI GHANDEHARI VICTOR
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationRisk factors for type 2 diabetes in groups stratified according to metabolic syndrome: a 10-year follow-up of The Tromsø Study
Risk factors for type 2 diabetes in groups stratified according to metabolic syndrome: a 10-year follow-up of The Tromsø Study European Journal of Epidemiology ISSN 0393-2990 Volume 26 Number 2 Eur J Epidemiol
More informationIs socioeconomic position related to the prevalence of metabolic syndrome? Influence of
Is socioeconomic position related to the prevalence of metabolic syndrome? Influence of social class across the life-course in a population-based study of older men Sheena E Ramsay, MPH 1, Peter H Whincup,
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More informationCardiovascular Risk Assessment and Management Making a Difference
Cardiovascular Risk Assessment and Management Making a Difference Norman Sharpe March 2014 Numbers and age-standardised mortality rates from all causes, by sex, 1950 2010 Death rates halved Life expectancy
More informationTEN-YEAR ABSOLUTE RISK ESTImates
ORIGINAL CONTRIBUTION CLINICIAN S CORNER Lifetime Risk and Years Lived Free of Total Cardiovascular Disease Scan for Author Video Interview John T. Wilkins, MD, MS Hongyan Ning, MD, MS Jarett Berry, MD,
More informationMETABOLIC SYNDROME IN OBESE CHILDREN AND ADOLESCENTS
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2012 vol. 116, no. 4 INTERNAL MEDICINE - PEDIATRICS ORIGINAL PAPERS METABOLIC SYNDROME IN OBESE CHILDREN AND ADOLESCENTS Ana-Maria Pelin 1, Silvia Mǎtǎsaru 2 University
More informationDiabetology & Metabolic Syndrome. Open Access RESEARCH
DOI 10.1186/s13098-016-0182-0 Diabetology & Metabolic Syndrome RESEARCH Open Access Impact of longitudinal status change in metabolic syndrome defined by two different criteria on new onset of type 2 diabetes
More informationDonald M. Lloyd-Jones, MD, ScM a,b, *, Alan R. Dyer, PhD a, Renwei Wang, MS a, Martha L. Daviglus, MD, PhD a, and Philip Greenland, MD a,b
Risk Factor Burden in Middle Age and Lifetime Risks for Cardiovascular and Non-Cardiovascular Death (Chicago Heart Association Detection Project in Industry) Donald M. Lloyd-Jones, MD, ScM a,b, *, Alan
More information5/28/2010. Pre Test Question
Myth of Metabolic Syndrome? C. W. Spellman, DO, PhD Professor and Associate Dean Research Dir. Center Diabetes and Metabolic Disorders Department Internal Medicine, Div. Endocrinology Texas Tech University
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More information2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE
2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE Massimo F Piepoli, MD, PhD, FESC, Piacenza, Italy on behalf of the 6 th Joint Task Force 2 3 Guidelines still based upon the principles of
More informationORIGINAL ARTICLE. Abstract. Introduction
ORIGINAL ARTICLE Health Education Hokenshido Program Reduced Metabolic Syndrome in the Amagasaki Visceral Fat Study. Three-Year Follow-up Study of 3,174 Japanese Employees Miwa Ryo 1, Tadashi Nakamura
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationCan metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies
Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies Naveed Sattar, Alex McConnachie, A Gerald Shaper, Gerard J Blauw, Brendan M Buckley,
More informationwell-targeted primary prevention of cardiovascular disease: an underused high-value intervention?
well-targeted primary prevention of cardiovascular disease: an underused high-value intervention? Rod Jackson University of Auckland, New Zealand October 2015 Lancet 1999; 353: 1547-57 Findings: Contribution
More informationCVD risk calculation
CVD risk calculation Cardiovascular disease (CVD) is the most common cause of death in Alberta, accounting for nearly one third (31%) of the overall deaths (1). The majority (90%) of the CVD cases are
More informationIdentification of subjects at high risk for cardiovascular disease
Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Identification of subjects at high risk for cardiovascular disease Lars Rydén Karolinska Institutet
More informationUsing the New Hypertension Guidelines
Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in
More informationAn evaluation of body mass index, waist-hip ratio and waist circumference as a predictor of hypertension across urban population of Bangladesh.
An evaluation of body mass index, waist-hip ratio and waist circumference as a predictor of hypertension across urban population of Bangladesh. Md. Golam Hasnain 1 Monjura Akter 2 1. Research Investigator,
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationThere really is an epidemic of type 2 diabetes
Diabetologia (2005) 48: 1459 1463 DOI 10.1007/s00125-005-1843-y FOR DEBATE S. Colagiuri. K. Borch-Johnsen. C. Glümer. D. Vistisen There really is an epidemic of type 2 diabetes Received: 22 December 2004
More information2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary
2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth
More informationMetabolic Syndrome.
www.bmiweightloss.com.au What is the metabolic syndrome? The was first described in 1988 by Gerald Reavson It was originally described as the clustering of four conditions These conditions when present
More informationStudent Paper PRACTICE-BASED RESEARCH
The Role of Clinical Pharmacists in Modifying Cardiovascular Disease Risk Factors Autumn Bagwell, PharmD. 1 ; Jessica W. Skelley, PharmD 2 ; Lana Saad, PharmD 3 ; Thomas Woolley, PhD 4 ; and DeeAnn Dugan,
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationShiftwork and cardiometabolic outcomes. Dr Anil Adisesh
Shiftwork and cardiometabolic outcomes Dr Anil Adisesh 1 FACULTY/PRESENTER DISCLOSURE Faculty: Dr Anil Adisesh Relationships with commercial interests: - None 2 Aims 1) Participants will be able to describe
More informationVascular calcification in patients with Diabetes Mellitus. Dr Jamie Bellinge University of Western Australia Royal Perth Hospital
Vascular calcification in patients with Diabetes Mellitus Dr Jamie Bellinge University of Western Australia Royal Perth Hospital Risk of cardiovascular disease Cardiovascular disease; - Stroke - Coronary
More informationScreening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm
Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm Anna J Waterreus and Jonathan D E Laugharne In 2001, the University of Western Australia s Centre
More informationAndrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University
CARDIOVASCULAR RISK FACTORS ORIGINAL ARTICLE Do We Correctly Assess the Risk of Cardiovascular Disease? Characteristics of Risk Factors for Cardiovascular Disease Depending on the Sex and Age of Patients
More informationModels of preventive care in clinical practice to achieve 25 by 25
Models of preventive care in clinical practice to achieve 25 by 25 Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College
More informationKnow Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up
Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up... Study Population: 340... Total Population: 500... Time Window of Baseline: 09/01/13 to 12/20/13... Time Window of Follow-up:
More informationClinical and Economic Summary Report. for Employers
Clinical and Economic Summary Report for Employers Magaly Rodriguez de Bittner, PharmD, CDE, FAPhA Director, P 3 Program Dawn Shojai, PharmD Assistant Director, P 3 Program P 3 Clinical & Economic Summary
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationEnergy Balance Equation
Energy Balance Equation Intake Expenditure Hunger Satiety Nutrient Absorption Metabolic Rate Thermogenesis Activity Eat to Live! Live to Eat! EAT TO LIVE Intake = Expenditure Weight Stable LIVE TO EAT
More informationFive chapters 1. What is CVD prevention 2. Why is CVD prevention needed 3. Who needs CVD prevention 4. How is CVD prevention applied 5. Where should CVD prevention be offered Shorter, more adapted to clinical
More informationPopulation models of health impact of combination polypharmacy
Population models of health impact of combination polypharmacy Global Summit on Combination Polypharmacy for CVD, 25 th September 2012 Dr Mark Huffman Northwestern University, Chicago Charity No: 1110067
More informationTHE HEALTH consequences of
ORIGINAL INVESTIGATION Weight Change, Weight Fluctuation, and Mortality S. Goya Wannamethee, PhD; A. Gerald Shaper, FRCP; Mary Walker, MA Objective: To examine the relation between weight change and weight
More informationEstablished Risk Factors for Coronary Heart Disease (CHD)
Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland
More informationRisks and benefits of weight loss: challenges to obesity research
European Heart Journal Supplements (2005) 7 (Supplement L), L27 L31 doi:10.1093/eurheartj/sui083 Risks and benefits of weight loss: challenges to obesity research Donna Ryan* Pennington Biomedical Research
More informationDiscussion points. The cardiometabolic connection. Cardiometabolic Risk Management in the Primary Care Setting
Session #5 Cardiometabolic Risk Management in the Primary Care Setting Sonja Reichert, MD MSc FCFP FACPM Betty Harvey, RNEC BScN MScN Amanda Mikalachki, RN BScN CDE S Discussion points Whom should we be
More informationSecondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION
Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION Dr Kornelia Kotseva National Heart & Lung Insitute Imperial College London, UK on behalf of all investigators participating
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular
More informationGender differences in coronary heart disease in Turkey
Original Article Gender differences in coronary heart disease in Turkey Mehmet Rami Helvaci 1, Hasan Kaya 2, Mehmet Gundogdu 3 ABSTRACT Objectives: To find out whether or not there are some gender differences
More informationObesity Causes Complications and Dietary Weight Loss Strategy
Obesity Causes Complications and Dietary Weight Loss Strategy A Tulasi Latha Department of Home Science, Acharya Nagarjuna University, Nagarjuna Nagar, AP - 522510, India. ABRTACT Background: Obesity is
More informationPredictive value of overweight in early detection of metabolic syndrome in schoolchildren
Predictive value of overweight in early detection of metabolic syndrome in schoolchildren Marjeta Majer, Vera Musil, Vesna Jureša, Sanja Musić Milanović, Saša Missoni University of Zagreb, School of Medicine,
More informationType 2 diabetes in Tuvalu: A drug use and chronic disease management evaluation. Prepared for the Ministry of Health, Tuvalu.
Type 2 diabetes in Tuvalu: A drug use and chronic disease management evaluation Prepared for the Ministry of Health, Tuvalu. 2012 Investigator Alexander Bongers Intern pharmacist, Royal Melbourne Hospital,
More informationRehabilitation and Research Training Center on Secondary Conditions in Individuals with SCI. James S. Krause, PhD
Disclosure The contents of this presentation were developed with support from educational grants from the Department of Education, NIDRR grant numbers H133B090005, H133B970011 and H133G010160. However,
More informationTrends In CVD, Related Risk Factors, Prevention and Control In China
Trends In CVD, Related Risk Factors, Prevention and Control In China Youfa Wang, MD, MS, PhD Associate Professor Center for Human Nutrition Department of International Health Department of Epidemiology
More informationPrevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini
Prevenzione cardiovascolare e cambiamento degli stili di vita Gian Franco Gensini Main causes of death worldwide at all ages (year:: 2005) 17.5 milion Preventing Chronic Diseases A vital investiment. WHO
More informationImpact of Lifestyle Modification to Reduce Cardiovascular Disease Event Risk of High Risk Patients with Low Levels of HDL C
Impact of Lifestyle Modification to Reduce Cardiovascular Disease Event Risk of High Risk Patients with Low Levels of HDL C Thomas P. Bersot, M.D., Ph.D. Gladstone Institute of Cardiovascular Disease University
More informationMafauzy Mohamed, Than Winn, GR Lekhraj Rampal*, Abdul Rashid AR, Mustaffa BE
Malaysian Journal of Medical Sciences, Vol. 12, No. 1, January 2005 (20-25) ORIGINAL ARTICLE A PRELIMENARY RESULT OF THE CARDIOVASCULAR RISK FACTORS INTERVENTION STUDY (PIKOM STUDY): DIABETES MELLITUS,
More informationWhy Do We Treat Obesity? Epidemiology
Why Do We Treat Obesity? Epidemiology Epidemiology of Obesity U.S. Epidemic 2 More than Two Thirds of US Adults Are Overweight or Obese 87.5 NHANES Data US Adults Age 2 Years (Crude Estimate) Population
More informationMetabolic syndrome and insulin resistance in an urban and rural adult population in Sri Lanka
Original Metabolic paper syndrome and insulin resistance in an urban and rural adult population in Sri Lanka Metabolic syndrome and insulin resistance in an urban and rural adult population in Sri Lanka
More informationCommunity Based Diabetes Prevention
Community Based Diabetes Prevention Melanie Davies Professor of Diabetes Medicine Outline NIHR Programme Grant proposal and update to progress The Vascular Check programme HbA1c debate Algorithm to detect
More informationAchieving a Culture of Employee Health and Wellness
Achieving a Culture of Employee Health and Wellness Mauret Brinser Executive Director, New Hampshire American Heart Association Mauret.brinser@heart.org Key Accomplishments of the Last Decade Established
More informationCut-Off Values of Visceral Fat Area and Waist-to-Height Ratio: Diagnostic Criteria for Obesity-Related Disorders in Korean Children and Adolescents
Original Article http://dx.doi.org/10.3349/ymj.2012.53.1.99 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 53(1):99-105, 2012 Cut-Off Values of Visceral Fat Area and Waist-to-Height Ratio: Diagnostic
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationCardiovascular Disease Prevention: Current Knowledge, Future Directions
Cardiovascular Disease Prevention: Current Knowledge, Future Directions Daniel Levy, MD Director, Framingham Heart Study Professor of Medicine, Boston University School of Medicine Editor-in-Chief, Journal
More informationLifetime Risk of Cardiovascular Disease Among Individuals with and without Diabetes Stratified by Obesity Status in The Framingham Heart Study
Diabetes Care Publish Ahead of Print, published online May 5, 2008 Lifetime Risk of Cardiovascular Disease Among Individuals with and without Diabetes Stratified by Obesity Status in The Framingham Heart
More informationT he prevalence of type 2 diabetes
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Two-Step Approach for the Prediction of Future Type 2 Diabetes Risk MUHAMMAD A. ABDUL-GHANI, MD, PHD 1 TAMAM ABDUL-GHANI, MSC 1 MICHAEL P.
More informationNutrition in Metabolic Syndrome Topic 24
Nutrition in Metabolic Syndrome Topic 24 Module 24.1 Diagnostic criteria for Metabolic Syndrome Learning Objectives: María Cristina Cuerda Compés Study the diagnostic criteria for Metabolic Syndrome; Define
More informationTackling Diabesity in Asia: People, politics, and prevention. Paul Zimmet AO Director Emeritus Baker IDI Heart and Diabetes Institute Melbourne
Tackling Diabesity in Asia: People, politics, and prevention Paul Zimmet AO Director Emeritus Baker IDI Heart and Diabetes Institute Melbourne Diabetes is a public health emergency in slow motion Ban Ki-Moon,
More informationDepok-Indonesia STEPS Survey 2003
The STEPS survey of chronic disease risk factors in Indonesia/Depok was carried out from February 2003 to March 2003. Indonesia/Depok carried out Step 1, Step 2 and Step 3. Socio demographic and behavioural
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationSocioeconomic status risk factors for cardiovascular diseases by sex in Korean adults
, pp.44-49 http://dx.doi.org/10.14257/astl.2013 Socioeconomic status risk factors for cardiovascular diseases by sex in Korean adults Eun Sun So a, Myung Hee Lee 1 * a Assistant professor, College of Nursing,
More informationCardiovascular Risk Factors among Diabetic Patients Attending a Nigerian Teaching Hospital. O Alao, S Adebisi, G Jombo, D Joseph, O Damulak, F Puepet
ISPUB.COM The Internet Journal of Endocrinology Volume 6 Number 1 Cardiovascular Risk Factors among Diabetic Patients Attending a Nigerian Teaching Hospital. O Alao, S Adebisi, G Jombo, D Joseph, O Damulak,
More informationEpidemiologic Measure of Association
Measures of Disease Occurrence: Epidemiologic Measure of Association Basic Concepts Confidence Interval for population characteristic: Disease Exposure Present Absent Total Yes A B N 1 = A+B No C D N 2
More informationIsolated Post-challenge Hyperglycemia: Concept and Clinical Significance
CLINICAL PRACTICE Isolated Post-challenge Hyperglycemia: Concept and Clinical Significance John MF. Adam*, Daniel Josten** ABSTRACT The American Diabetes Association has strongly recommended that fasting
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationPrevalence of metabolic syndrome among 40- and 50-year-old inhabitants of Wroclaw, Poland
ORIGINAL ARTICLE Annals of Agricultural and Environmental Medicine 2012, Vol 19, No 3, 551-556 www.aaem.pl Prevalence of metabolic syndrome among 40- and 50-year-old inhabitants of Wroclaw, Poland Rafał
More informationDOI /ymj pissn: , eissn: Yonsei Med J 52(2): , 2011
Original Article DOI 10.3349/ymj.2011.52.2.220 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 52(2):220-226, 2011 A Comparison of Predictability of Cardiovascular Events between Each Metabolic Component
More informationHeart health CHD management gaps in general practice
professional practice Nancy Huang MBBS, DipRACOG, MPH, is National Manager Clinical Programs, Heart Foundation, Melbourne, Victoria. nancy.huang@heartfoundation.org.au Marcus Daddo BSc(Hons), is Manager
More informationModelling Reduction of Coronary Heart Disease Risk among people with Diabetes
Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes Katherine Baldock Catherine Chittleborough Patrick Phillips Anne Taylor August 2007 Acknowledgements This project was made
More informationMETABOLIC SYNDROME IN TYPE-2 DIABETES MELLITUS
METABOLIC SYNDROME IN TYPE-2 DIABETES MELLITUS S.M. Sohail Ashraf 1, Faisal Ziauddin 2, Umar Jahangeer 3 ABSTRACT Objective: To find out the prevalence of metabolic syndrome in type-2 Diabetes Mellitus
More informationReport Operation Heart to Heart
Report Operation Heart to Heart Elkhorn Logan Valley Public Health Department (Burt, Cuming, Madison, and Stanton Counties) Gina Uhing, Health Director Ionia Research Newcastle, Nebraska Joseph Nitzke
More informationPrevalence of Diabetes Mellitus among Non-Bahraini Workers Registered in Primary Health Care in Bahrain
Prevalence of Diabetes Mellitus among Non-Bahraini Workers Page 1 of 10 Bahrain Medical Bulletin, Vol.25, No.1, March 2003 Prevalence of Diabetes Mellitus among Non-Bahraini Workers Registered in Primary
More information